CN103405755A - 一种治疗原发性骨质疏松症的药物组合物 - Google Patents
一种治疗原发性骨质疏松症的药物组合物 Download PDFInfo
- Publication number
- CN103405755A CN103405755A CN2013103842350A CN201310384235A CN103405755A CN 103405755 A CN103405755 A CN 103405755A CN 2013103842350 A CN2013103842350 A CN 2013103842350A CN 201310384235 A CN201310384235 A CN 201310384235A CN 103405755 A CN103405755 A CN 103405755A
- Authority
- CN
- China
- Prior art keywords
- bovis seu
- seu bubali
- calcium
- wood frog
- pulverize
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title description 4
- 239000011575 calcium Substances 0.000 claims abstract description 37
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 37
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 24
- 102000008186 Collagen Human genes 0.000 claims abstract description 18
- 108010035532 Collagen Proteins 0.000 claims abstract description 18
- 150000007949 saponins Chemical class 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 14
- 229930182490 saponin Natural products 0.000 claims abstract description 14
- 235000017709 saponins Nutrition 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims abstract 2
- 239000007902 hard capsule Substances 0.000 claims abstract 2
- 239000006187 pill Substances 0.000 claims abstract 2
- 239000007901 soft capsule Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 241000191896 Rana sylvatica Species 0.000 claims description 24
- 102000002322 Egg Proteins Human genes 0.000 claims description 23
- 108010000912 Egg Proteins Proteins 0.000 claims description 23
- 210000004681 ovum Anatomy 0.000 claims description 23
- 241000195474 Sargassum Species 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000021419 vinegar Nutrition 0.000 claims description 7
- 239000000052 vinegar Substances 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 238000010791 quenching Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 8
- 229920001436 collagen Polymers 0.000 abstract description 3
- 210000003101 oviduct Anatomy 0.000 abstract description 3
- -1 troches Substances 0.000 abstract description 2
- 241000283690 Bos taurus Species 0.000 abstract 2
- 240000000031 Achyranthes bidentata Species 0.000 abstract 1
- 244000269722 Thea sinensis Species 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 235000001465 calcium Nutrition 0.000 description 31
- 241000700159 Rattus Species 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 15
- 210000000689 upper leg Anatomy 0.000 description 10
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000011574 phosphorus Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000037182 bone density Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 3
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 3
- 206010039984 Senile osteoporosis Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001009 osteoporotic effect Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 238000004380 ashing Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004221 bone function Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical class N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000000474 heel Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310384235.0A CN103405755B (zh) | 2013-08-29 | 2013-08-29 | 一种治疗原发性骨质疏松症的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310384235.0A CN103405755B (zh) | 2013-08-29 | 2013-08-29 | 一种治疗原发性骨质疏松症的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103405755A true CN103405755A (zh) | 2013-11-27 |
CN103405755B CN103405755B (zh) | 2014-08-13 |
Family
ID=49598828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310384235.0A Active CN103405755B (zh) | 2013-08-29 | 2013-08-29 | 一种治疗原发性骨质疏松症的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103405755B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108066740A (zh) * | 2016-11-07 | 2018-05-25 | 亿菩升(上海)生物科技有限公司 | 牛骨肽在制备治疗和预防骨质疏松的药物和食物中的应用 |
CN108477610A (zh) * | 2018-03-12 | 2018-09-04 | 大连军门保健食品有限公司 | 一种含有林蛙卵提取物的保健食品 |
CN108685101A (zh) * | 2018-05-16 | 2018-10-23 | 林万君 | 林蛙肽菊粉 |
CN108813633A (zh) * | 2018-05-16 | 2018-11-16 | 林万君 | 林蛙卵肽粉 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926982A (zh) * | 2010-08-26 | 2010-12-29 | 烟台大洋制药有限公司 | 一种具有增强骨密度作用的药品或者保健食品 |
-
2013
- 2013-08-29 CN CN201310384235.0A patent/CN103405755B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926982A (zh) * | 2010-08-26 | 2010-12-29 | 烟台大洋制药有限公司 | 一种具有增强骨密度作用的药品或者保健食品 |
Non-Patent Citations (2)
Title |
---|
任心慈等: "牛膝总皂苷对维甲酸致骨质疏松大鼠骨代谢的影响", 《中国实验方剂学杂志》, vol. 17, no. 4, 28 February 2011 (2011-02-28) * |
李中平等: "中国雪蛤酶解液预防去卵巢大鼠骨质疏松", 《中国组织工程研究与临床康复》, vol. 14, no. 33, 13 August 2010 (2010-08-13) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108066740A (zh) * | 2016-11-07 | 2018-05-25 | 亿菩升(上海)生物科技有限公司 | 牛骨肽在制备治疗和预防骨质疏松的药物和食物中的应用 |
CN108477610A (zh) * | 2018-03-12 | 2018-09-04 | 大连军门保健食品有限公司 | 一种含有林蛙卵提取物的保健食品 |
CN108685101A (zh) * | 2018-05-16 | 2018-10-23 | 林万君 | 林蛙肽菊粉 |
CN108813633A (zh) * | 2018-05-16 | 2018-11-16 | 林万君 | 林蛙卵肽粉 |
Also Published As
Publication number | Publication date |
---|---|
CN103405755B (zh) | 2014-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101288686B (zh) | 一种增加骨密度的保健制剂及制备方法 | |
CN101428056A (zh) | 一种改善中老年女性骨质疏松症的保健制剂及制备方法 | |
CN105012711B (zh) | 一种用于缓解体力疲劳和补肾壮阳的组合物及其制备方法 | |
CN103405755B (zh) | 一种治疗原发性骨质疏松症的药物组合物 | |
CN108653644A (zh) | 一种温肾助阳的药物组合物及其制备方法和用途 | |
CN106938005A (zh) | 一种用于治疗骨质疏松的中药组合物 | |
CN104721678A (zh) | 高良姜提取物在制备抗骨质疏松保健食品及药品方面的应用 | |
CN103349674B (zh) | 一种增加骨密度、防治骨质疏松症的龟甲林蛙油组合物 | |
CN104257762B (zh) | 一种药物组合物及其预防和治疗骨质疏松的用途 | |
CN104001157B (zh) | 一种防治骨质疏松症的复方制剂及其制备方法 | |
CN103330837B (zh) | 一种治疗绝经妇女骨质疏松症的中药组合物 | |
CN102626463A (zh) | 一种增加骨密度、防治骨质疏松症的天然药物组合物 | |
CN104225067B (zh) | 用于治疗绝经后骨质疏松的中药组合物、制备方法和用途 | |
CN106361947A (zh) | 一种用于治疗骨质疏松的中药制备方法 | |
US11975052B2 (en) | Compound composition for improving bone health and preparation and application thereof | |
CN102114070B (zh) | 一种治疗骨质疏松的复方中药及其制备方法 | |
CN107812039A (zh) | 一种具有补肾健骨功能的牛大力中药组合物及其制备方法 | |
CN102526444A (zh) | 一种补肾壮阳的中药组合物及其制备方法 | |
CN106963845A (zh) | 一种用于保坤延春的中药组合物及其制备方法 | |
CN108450964A (zh) | 治疗和预防女性经期综合症的保健组合物及其制备方法 | |
CN104189693B (zh) | 一种治疗绝经后骨质疏松症的中药组合物 | |
CN103768158A (zh) | 一种防治骨质疏松症的药物组合物及其制备方法 | |
CN105768094A (zh) | 一种增加骨密度的保健食品及其制备方法 | |
CN106421099A (zh) | 一种改善男性性功能的药物及其制备方法 | |
CN1498629A (zh) | 一种治疗骨质疏松症的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180321 Address after: No. 555, Sinpo Road, hi-tech North District, Changchun, Jilin Patentee after: Changchun Renren Pharmaceutical Co., Ltd. Address before: 130012 Changchun high tech Zone, Jilin pioneering Street No. 155 Patentee before: Zhao Quancheng |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition for treating primary osteoporosis Effective date of registration: 20190617 Granted publication date: 20140813 Pledgee: Jilin Zhongxin science and technology credit Company limited by guarantee Pledgor: Changchun Renren Pharmaceutical Co., Ltd. Registration number: 2019220000020 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20191218 Granted publication date: 20140813 Pledgee: Jilin Zhongxin science and technology credit Company limited by guarantee Pledgor: Changchun Renren Pharmaceutical Co., Ltd. Registration number: 2019220000020 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition for treating primary osteoporosis Effective date of registration: 20191226 Granted publication date: 20140813 Pledgee: Jilin Zhongxin Technology Credit Financing Guarantee Co., Ltd Pledgor: Changchun Renren Pharmaceutical Co., Ltd. Registration number: Y2019220000067 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |